Stocks in play: Newscope Capital Corporation

Announced that its wholly-owned subsidiary, PharmaTher has entered into an exclusive license agreement with The University of Kansas for the development and commercialization for the intellectual property of ketamine in the treatment amyotrophic lateral sclerosis (“ALS”), also known as Lou Gehrig's disease. The University of Kansas Medical Center inventors Dr. Richard J. Barohn, M.D., John A. Stanford, Ph.D., and Dr. Matthew Macaluso, D.O., have made the promising discovery that ketamine can be administered as an effective treatment for ALS. Their preclinical research has shown that the administration of ketamine preserves muscle function in advancing ALS and increases life expectancy when given in the early stages of muscle decline. Currently, there is no known cure for ALS. Peak sales for a new drug to treat ALS can achieve over USD $1 billion. Newscope Capital Corporation shares C.PHRM are trading up 2 cents at $0.34.

Read:

• CBD Beverages Could Offer Investors a $3 Billion Market Opportunity

• Psilocybin Could Help Curb Cravings and Shut Off Appetite

• Why Now is Still a Good Time to Invest in Gold

• More and More Countries are Shifting Towards Plant-Based Diets

• Mobile Gaming Could Create a $120 Billion Opportunity in 2021

• This May be the Clearest Sign the Future Will be Plant-Based

• With Psilocybin, Significant Progress is Being Made with Substance Use Disorders

• Having Founded a Billion Dollar Miner Once, This CEO is Now Targeting Silver in Mexico

• Some of The Top Cryptocurrency Bets are the Mining Stocks

• Ketamine Could Potentially Increase Life Expectancy for Lou Gehrig’s Disease Patients

• Consumers Are Now Demanding EMR Protection for their Pets

• Innovators Identify Crucial Advancements to Uncover Medical Breakthroughs From Psychedelics